Confirmatory Trial Early Planning Is Essential To Address Potential Problems
Executive Summary
Sponsors should develop a strategy to address potential challenges to completion of accelerated approval confirmatory studies in advance of conducting the trials, members of FDA's Oncologic Drugs Advisory Committee suggested Nov. 8
You may also be interested in...
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.
FDA Will Make Advisory Committee Review Of Accelerated Approvals An Annual Event
FDA plans to hold a yearly session with its Oncology Drugs Advisory Committee on cancer drugs granted accelerated approval as a means of holding sponsors' feet to the fire with regard to conducting confirmatory trials.